Helping Children Receive an Earlier Autism Diagnosis

Earlier Diagnosis + Earlier Intervention = Better Outcomes

The NPDX ASD blood test is a new diagnostic tool that may lead to an earlier diagnosis for children with autism spectrum disorder (ASD).

Our blood test is validated by our National Institutes of Mental Health clinical study, the largest study to evaluate the metabolism of children with autism.

The results of our clinical study were published in the scientific journal, Biological Psychiatry.

We improve the lives of children and families living with autism spectrum disorder by providing tools for earlier diagnosis and more precise treatment.

Earlier access to specialty care and treatments improve outcomes

Talk to your healthcare Provider (pediatrician, family doctor) about requesting our test for your child.

Print the NeuroPointDX brochure which summarizes our company and our autism test for your Provider.

Sign-up to receive updates on our progress developing tools for autism diagnosis and treatment.

Posters and Publications

NeuroPointDX, through its parent company Stemina Biomarker Discovery, has published papers in peer-reviewed journals and presented research at meetings around the world.

Unique Metabolic Signatures Associated with Autism Spectrum Disorder (ASD) Detect More than 50% of individuals with ASD in Children’s Autism Metabolome Project (CAMP)

MADISON, Wisc.--(BUSINESS WIRE)-- In a paper published online this week in Autism Research, scientists at NeuroPointDX, a division of Stemina Biomarker Discovery, Inc., in collaboration with researchers at the UC Davis MIND Institute and academic and clinical institutions across the country, report new findings from the Children’s Autism Metabolome Project or CAMP. Analysis of blood samples from CAMP, the largest[...]

NeuroPointDX, through its parent company Stemina Biomarker Discovery, has published papers in peer-reviewed journals and presented research at meetings around the world.

Identification of Neurotransmitter-Associated and Other Metabotypes: Further Stratification of the Children’s Autism Metabolome Project (CAMP) ASD Subjects

Presented at the 2019 Annual Meeting of the International Society for Autism Research (INSAR) in Montreal, Ontario, Canada in May 2019. The Children’s Autism Metabolome Project (CAMP), ClinicalTrials.gov: NCT02548442, recruited 1,100 children for metabolomic analyses to identify altered metabolism associated with ASD. Previous research identified ASD subjects associated with branched-chain amino acid (BCAA) dysregulation. With this[…]

News

Unique Metabolic Signatures Associated with Autism Spectrum Disorder (ASD) Detect More than 50% of individuals with ASD in Children’s Autism Metabolome Project (CAMP)

MADISON, Wisc.--(BUSINESS WIRE)-- In a paper published online this week in Autism Research, scientists at NeuroPointDX, a division of Stemina Biomarker Discovery, Inc., in collaboration with researchers at the UC Davis MIND Institute and academic and clinical institutions across the country, report new findings from the Children’s Autism Metabolome Project or CAMP. Analysis of blood samples from CAMP, the largest[...]